<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33123">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675452</url>
  </required_header>
  <id_info>
    <org_study_id>20150161</org_study_id>
    <secondary_id>2015-004777-32</secondary_id>
    <nct_id>NCT02675452</nct_id>
  </id_info>
  <brief_title>AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma.</brief_title>
  <official_title>A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 176 in Subjects With Relapsed or Refractory Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At least one dose level of AMG 176 will achieve acceptable safety and tolerability in
      subjects with relapsed or refractory multiple myeloma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, first-in-human, multicenter; non-randomized, open-label and
      dose-exploration study of AMG 176 administered IV in subjects with relapsed or refractory
      multiple myeloma.

      The study will be conducted in three parts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events and significant laboratory abnormalities</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluate PK on different cohorts</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine the maximum tolerated combination (MTC)</measure>
    <time_frame>6 months on treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demonstrate investigational product inactivation of MCL-1</measure>
    <time_frame>6 months on treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary efficacy according to the International Myeloma Working Group uniform response criteria</measure>
    <time_frame>6 months on treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">85</enrollment>
  <condition>Relapsed or Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>AMG 176 - Part 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1a - dose exploration of the intervention, AMG 176</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 1b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 1b dose exploration. The intervention is AMG 176</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AMG 176 - Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Part 2 Combination therapy The intervention is AMG 176</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 176</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>AMG 176 - Part 1a</arm_group_label>
    <arm_group_label>AMG 176 - Part 1b</arm_group_label>
    <arm_group_label>AMG 176 - Part 2</arm_group_label>
    <other_name>Study Investigational Product (IP)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA: -Pathologically documented, multiple myeloma relapsed or refractory
        disease after at least 2 lines of therapy, -Must be willing and able to undergo bone
        marrow biopsy at screening, -Measurable disease per the IMWG response criteria, -Eastern
        Cooperative Oncology Group (ECOG) performance status of â‰¤ 2, -Satisfactory hematological
        function without transfusion or growth factor support, -Subjects should not have received
        platelet transfusions for at least 1 week prior to screening, -Hemoglobin &gt; 8 g/dL,
        -Subjects may receive RBC transfusions or receive supportive care), -Other Inclusion
        Criteria May Apply.

        EXCLUSION CRITERIA: -Previously received an allogeneic stem cell transplant within 6
        months OR having received immunosuppressive therapy within the last three months OR having
        signs or symptoms of acute or chronic graft-versus-host disease, -Autologous stem cell
        transplant less than 90 days prior to study day 1, -Multiple myeloma with IgM subtype,
        -POEMS syndrome, -Existing plasma cell leukemia, -Waldenstrom's macroglobulinemia,
        -Amyloidosis, -Glucocorticoid therapy (prednisone &gt; 30 mg/day or equivalent) within 7 days
        prior to starting treatment, -Topical or inhaled corticosteroids are permitted, -Infection
        requiring intravenous anti-infective treatments within 1 week of study enrollment (day 1),
        -Other exclusion Criteria May Apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-6613</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prahran</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 24, 2017</lastchanged_date>
  <firstreceived_date>December 22, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
